Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inovio Pharmaceuticals Inc (NASDAQ:INO)

4.72
Delayed Data
As of Nov 17
 +0.08 / +1.72%
Today’s Change
4.20
Today|||52-Week Range
9.86
-31.99%
Year-to-Date
Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss
Nov 09 / Zacks.com - Paid Partner Content
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?
Nov 07 / Zacks.com - Paid Partner Content
What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?
Nov 07 / Zacks.com - Paid Partner Content
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
Nov 07 / Zacks.com - Paid Partner Content
5 Biotech Stocks Well Poised to Surpass Expectations in Q3
Nov 07 / Zacks.com - Paid Partner Content
Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?
Nov 06 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close4.64
Today’s open4.62
Day’s range4.62 - 4.79
Volume923,360
Average volume (3 months)1,487,176
Market cap$426.2M
Dividend yield--
Data as of 4:00pm ET, 11/17/2017

Growth & Valuation

Earnings growth (last year)-129.55%
Earnings growth (this year)--
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-12.83%
P/E ratioNM
Price/Sales14.37
Price/Book2.84

Competitors

 Today’s
change
Today’s
% change
PETQPetIQ Inc-0.69-3.29%
SCMPSucampo Pharmaceutic...+0.20+1.93%
KALAKala Pharmaceuticals...+0.14+0.75%
GTHXG1 Therapeutics Inc0.000.00%
Data as of 4:00pm ET, 11/17/2017

Financials

Next reporting dateMarch 15, 2018
EPS forecast (this quarter)-$0.31
Annual revenue (last year)$35.4M
Annual profit (last year)-$73.7M
Net profit margin-208.49%

Profile

Sector
Health Technology
Industry
Medical Specialties
President, Chief Executive Officer &
Director
J. Joseph Kim
Chief Operating Officer
Niranjan Y. Sardesai
Corporate headquarters
Plymouth Meeting, Pennsylvania

Forecasts